Provided by Tiger Trade Technology Pte. Ltd.

Beam Therapeutics, Inc.

25.18
-1.6550-6.17%
Pre-market: 25.650.4743+1.88%07:45 EDT
Volume:2.85M
Turnover:72.77M
Market Cap:2.60B
PE:-30.06
High:26.70
Open:26.70
Low:25.11
Close:26.83
52wk High:38.26
52wk Low:19.57
Shares:103.29M
Float Shares:91.60M
Volume Ratio:1.32
T/O Rate:3.11%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8376
EPS(LYR):-0.8100
ROE:-8.18%
ROA:-17.01%
PB:2.44
PE(LYR):-31.08

Loading ...

Beam Therapeutics Q2 License and Collaboration Revenue USD 490 Thousand

THOMSON REUTERS
·
Aug 04

Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of Beam-302 Trial in Alpha-1 Antitrypsin Deficiency (Aatd)

THOMSON REUTERS
·
Aug 04

Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)

GlobeNewswire
·
Aug 04

Scribe's Genetic Editing Aims to Prevent Heart Attacks

Dow Jones
·
Jul 30

Beam Therapeutics Announces Press Release Availability

Reuters
·
Jul 23

Beam Therapeutics (BEAM) Following Ark Invest Interest And Clinical Milestones Looks Undervalued

Simply Wall St.
·
Jul 23

TD Cowen says arbitration decision removes overhang for Prime Medicine’s PM647

TIPRANKS
·
Jul 09

Resolution in favor of Prime has limited impact to Beam, says BofA

TIPRANKS
·
Jul 08

Prime Medicine Wins Arbitration with Beam over AATD Therapy PM647

Reuters
·
Jul 08

Ambarella, Beam, United Micro, Hyperscale Data, Atai Beckley Shocking Insider Moves

TIPRANKS
·
Jul 04

Beam Therapeutics CEO John M. Evans Disposes of 49,000 Common Shares Worth $1.72 Million

Reuters
·
Jul 02

FMR Reports $10.04 Million Beam Therapeutics Common Share Sale

Reuters
·
Jun 30

Beam Therapeutics (BEAM) Could Be 78% Undervalued As FDA Clears BEAM 304

Simply Wall St.
·
Jun 25

Why Beam Therapeutics (BEAM) Is Up 16.1% After FDA Clears Platform-Based PKU Gene-Editing Trial

Simply Wall St.
·
Jun 20

Beam Therapeutics says FDA clears IND for PKU candidate BEAM-304

Reuters
·
Jun 18

Beam Therapeutics Announces Clearance of Investigational New Drug Application for Beam-304 for the Treatment of Phenylketonuria (Pku) by the United States (U.S.) Food and Drug Administration

THOMSON REUTERS
·
Jun 18

Beam Stockholders Back Board, Leadership at Annual Meeting

TIPRANKS
·
Jun 09

Beam Therapeutics shareholders elect Class III directors at annual meeting

Reuters
·
Jun 09

Beam Therapeutics (BEAM) Gets a Buy from Canaccord Genuity

TIPRANKS
·
May 21

Beam Therapeutics presents Phase 1/2 data for BEAM-302

TIPRANKS
·
May 19